Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
- PMID: 29270787
- DOI: 10.1007/s00259-017-3909-8
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
Abstract
ᅟ: FDG PET/CT (18F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine experts defined new visual descriptive criteria (Italian Myeloma criteria for Pet Use: IMPeTUs) to standardize FDG PET/CT evaluation in MM patients. The aim of this study was to assess IMPeTUs reproducibility on a large prospective cohort of MM patients.
Materials and methods: Patients affected by symptomatic MM who had performed an FDG PET/CT at baseline (PET0), after induction (PET-AI), and the end of treatment (PET-EoT) were prospectively enrolled in a multicenter trial (EMN02)(NCT01910987; MMY3033). After anonymization, PET images were uploaded in the web platform WIDEN® and hence distributed to five expert nuclear medicine reviewers for a blinded independent central review according to the IMPeTUs criteria. Consensus among reviewers was measured by the percentage of agreement and the Krippendorff's alpha. Furthermore, on a patient-based analysis, the concordance among all the reviewers in terms of positivity or negativity of the FDG PET/CT scan was tested for different thresholds of positivity (Deauville score (DS 2, 3, 4, 5) for the main parameters (bone marrow, focal score, extra-medullary disease).
Results: Eighty-six patients (211 FDG PET/CT scans) were included in this analysis. Median patient age was 58 years (range, 35-66 years), 45% were male, 15% of them were in stage ISS (International Staging System) III, and 42% had high-risk cytogenetics. The percentage agreement was superior to 75% for all the time points, reaching 100% of agreement in assessing the presence skull lesions after therapy. Comparable results were obtained when the agreement analysis was performed using the Krippendorff's alpha coefficient, either in every single time point of scanning (PET0, PET-AI or PET-EoT) or overall for all the scans together. DS proved highly reproducible with the highest reproducibility for score 4.
Conclusions: IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma. A prospective clinical validation of IMPeTUs criteria is underway.
Keywords: FDG PET/CT; IMPeTUs; Interpretation criteria; Multiple myeloma; Standardization.
Similar articles
-
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16. Eur J Nucl Med Mol Imaging. 2016. PMID: 26475305
-
F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.Ann Hematol. 2011 Jan;90(1):81-7. doi: 10.1007/s00277-010-1037-7. Epub 2010 Aug 6. Ann Hematol. 2011. PMID: 20690019 Clinical Trial.
-
The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs).EJNMMI Res. 2021 Oct 9;11(1):100. doi: 10.1186/s13550-021-00846-y. EJNMMI Res. 2021. PMID: 34628525 Free PMC article.
-
18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma.PET Clin. 2022 Jul;17(3):415-430. doi: 10.1016/j.cpet.2022.03.001. PET Clin. 2022. PMID: 35717100 Review.
-
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Lancet Oncol. 2017. PMID: 28368259 Review.
Cited by
-
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25. Eur J Nucl Med Mol Imaging. 2021. PMID: 33099659
-
The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.Contrast Media Mol Imaging. 2018 Jul 30;2018:4198673. doi: 10.1155/2018/4198673. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 30154686 Free PMC article.
-
New Developments in Myeloma Treatment and Response Assessment.J Nucl Med. 2023 Sep;64(9):1331-1343. doi: 10.2967/jnumed.122.264972. Epub 2023 Aug 17. J Nucl Med. 2023. PMID: 37591548 Free PMC article.
-
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.J Clin Med. 2020 Jul 7;9(7):2142. doi: 10.3390/jcm9072142. J Clin Med. 2020. PMID: 32645952 Free PMC article. Review.
-
Role of FDG PET in the staging of multiple myeloma.Skeletal Radiol. 2022 Jan;51(1):31-41. doi: 10.1007/s00256-021-03771-2. Epub 2021 Apr 4. Skeletal Radiol. 2022. PMID: 33813607 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical